1. International Journal of Cardiology
Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS study 
Masato Nakamura, Takaaki Isshiki, Takeshi Kimura, Hisao Ogawa, Hiroyoshi Yokoi, Shinsuke Nanto, Morimasa Takayama, Kazuo Kitagawa, Yasuo Ikeda, Shigeru Saito 
International Journal of Cardiology 
Volume 182, Pages (March 2015)
DOI: /j.ijcard
Copyright © 2015 The Authors Terms and Conditions

2. Fig. 1
Time-course of platelet reactivity determined by the VerifyNow® P2Y12 assay after the loading dose and during the maintenance dose phase. *p< vs. clopidogrel by repeated measures ANOVA; the least square mean in the model was compared among groups at each time point, and time points showing a significant difference are marked with an asterisk. LD: loading dose; MD: maintenance dose; PRU: platelet reactivity unit.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions

3. Fig. 2
Platelet reactivity determined by the VerifyNow® P2Y12 assay at 5–12h after administration of the loading dose. (A) All patients treated with prasugrel or clopidogrel. (B) All patients with or without major adverse cardiovascular events within 3days after percutaneous coronary intervention. MACE: major adverse cardiovascular events; PRU: platelet reactivity unit.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions

4. Fig. 3
Receiver operating characteristic curve for platelet reactivity units determined using the VerifyNow® P2Y12 assay. AUC: area under the curve; CI: confidence interval.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions

5. Fig. 4
Cumulative incidence of major adverse cardiovascular events from baseline through to 24weeks according to platelet reactivity units ≤262 or >262 at 5–12h after the loading dose. The inset shows the cumulative incidence from baseline through to day 3. CI: confidence interval; MACE: major adverse cardiovascular events; OR: odds ratio; PRU: platelet reactivity unit.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions

6. Fig. 5
Proportions of patients with platelet reactivity units >262. PRU: platelet reactivity unit.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions

7. Fig. 6
Proportion of patients with platelet reactivity units ≤262 at 5–12h after the loading dose. The significance of differences was tested using the χ2 test. PRU: platelet reactivity unit.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions

8. Fig. 7
Effects of normal function or reduced-function CYP2C19 alleles on platelet reactivity. (A) Patients with reduced-function CYP2C19 alleles. (B) Patients with normal-function CYP2C19 alleles. *p< vs. clopidogrel-treated patients by repeated measures ANOVA; the least square mean in the model was compared among groups at each time point, and time points showing a significant difference are marked with an asterisk. PCI: percutaneous coronary intervention; PRU: platelet reactivity unit.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2015 The Authors Terms and Conditions